Alpha Tau Medical (NASDAQ:DRTS) Announces Earnings Results

Posted by Geri Gentry on May 19th, 2026

Alpha Tau Medical (NASDAQ:DRTS – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13), Zacks reports.

Alpha Tau Medical Trading Down 3.2%

DRTS opened at $10.03 on Tuesday. The firm has a market capitalization of $882.74 million, a P/E ratio of -18.92 and a beta of 1.11. The firm’s 50 day moving average is $7.70 and its 200-day moving average is $6.38. Alpha Tau Medical has a 52-week low of $2.81 and a 52-week high of $10.81. The company has a quick ratio of 7.45, a current ratio of 7.45 and a debt-to-equity ratio of 0.08.

Institutional Trading of Alpha Tau Medical

A number of hedge funds have recently made changes to their positions in DRTS. Envestnet Asset Management Inc. bought a new stake in shares of Alpha Tau Medical in the third quarter worth $62,000. Bank of America Corp DE raised its holdings in Alpha Tau Medical by 2,779.1% in the third quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock valued at $101,000 after acquiring an additional 21,677 shares in the last quarter. Wells Fargo & Company MN raised its holdings in Alpha Tau Medical by 291.7% in the fourth quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock valued at $116,000 after acquiring an additional 17,500 shares in the last quarter. Millennium Management LLC acquired a new stake in Alpha Tau Medical in the third quarter valued at $170,000. Finally, Mariner LLC raised its holdings in Alpha Tau Medical by 185.8% in the third quarter. Mariner LLC now owns 123,250 shares of the company’s stock valued at $556,000 after acquiring an additional 80,129 shares in the last quarter. Hedge funds and other institutional investors own 2.65% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on DRTS shares. Zacks Research upgraded shares of Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 17th. HC Wainwright lifted their price objective on shares of Alpha Tau Medical from $12.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. LADENBURG THALM/SH SH lifted their price objective on shares of Alpha Tau Medical from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Piper Sandler reiterated a “neutral” rating and set a $5.00 price objective on shares of Alpha Tau Medical in a research note on Wednesday, March 4th. Finally, Citigroup lifted their price objective on shares of Alpha Tau Medical from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Alpha Tau Medical has a consensus rating of “Hold” and a consensus price target of $10.75.

Read Our Latest Stock Analysis on DRTS

Alpha Tau Medical Company Profile

(Get Free Report)

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.